Table 2.
Treatment of COVID-19 in LT recipients among different series.
| Patients (n) | Time from LT (years)(median) | Immunosuppression modification (Reduction or withdrawal) | Specific treatment | |||||
|---|---|---|---|---|---|---|---|---|
| Calcineurin inhibitors | Antimetabolites | Corticosteroids | Remdesivir | Tocilizumab | ||||
| Lee et al., 2020 | 38 | 3.8 (0.02–28.2) | Reduction: 15/24 (63%) | Reduction:13/13 (100%) | 5/24 (21%) | NA | NA | |
| Beccheti et al., 2020 | 57 | 6 (2–13) | Reduction: 24% (12/50) Withdrawal: 14% (7/50) | Reduction: 4% (1/26) Withdrawal: 31% (8/26) | 19 (35%) | 0 | 1 (2%) | |
| Webb et al., 2020 | 151 | NR | NR | NR | 0 (0%) | 6 (4%) | 2 (1%) | |
| Rabiee, Sadowski et al 2020 | 117 | 4 (11) | Reduction: 21/73 (29%) | 4 (4%) | 3 (3%) | NA | ||
| Colmenero et al., 2021 | 111 | 8.75 (3–14) | NR | NR | 12 (13%) | 1 (1%) | 15 (16%) Mostly in severe cases | |
| Belli et al., 2021 | 243 | 8 (3–15) | Reduction: 38/162 (23%); Withdrawal: 16/162 (10%) | Withdrawal: 35/119 (29%) | 34(13%) | 1 (0.5%) | 15 (6%) | |
| Dumortier et al., 2021 | 91 | 7,1 (2,8–14) | Withdrawal: 7 (13%) | 6 (9%) | 2 (3%) | 1 (2%) | ||
Data expressed as n (%). NA: not available.